期刊文献+

氟伐他汀对糖尿病大鼠肾脏的保护作用 被引量:1

Effects of fluvastatin on the expression of transforming growth factor β1 in the kidney of diabetic rats
原文传递
导出
摘要 目的采用糖尿病大鼠模型,观察氟伐他汀对大鼠肾脏保护作用的机制。方法以链脲佐菌素(STZ)制备糖尿病大鼠模型,将SD大鼠随机分为正常对照组、糖尿病组、小剂量氟伐他汀治疗组2mg/(kg·d)和大剂量氟伐他汀治疗组4mg/(kg·d)。4周后检测各组大鼠血胆固醇、甘油三酯、血肌酐和24h尿蛋白,用RT-PCR检测肾组织转化生长因子(TGF-β1)的表达。结果糖尿病大鼠肾组织TGF-β1表达较正常肾组织增高,治疗4周后,氟伐他汀对血脂水平、蛋白尿无影响,但可明显降低糖尿病肾病大鼠肾小管间质中TGF-β1的表达,且随剂量增多TGF-β1下降更明显。结论氟伐他汀对糖尿病大鼠肾脏保护作用可能通过非依赖降脂的保护作用,其机制至少部分与下调肾小管间质中TGF-β1表达有关。 Objective To study the protective effects of fluvastatin on the renal lesions in diabetic rat. Methods The model of diabetic rats was induced by streptozotocin. SD rats were random divided into four groups : Control group, diabetic rats group, low-dose fluvastatin group 2mg/( kg· d) and high-dose fluvastatin group 4 mg/( kg·d). After treatment for 4 weeks, serum cholesterol, serum creatinine and urinary protein were measured respectively. The expression of TGF 131 in the renal cortex was determined by RT-PCR. Results Fluvas- tatin inhibited the expression of TGF-β1 mRNA in a dose-dependent manner, and had no influence on urinary protein, serum cholesterol and serum creatinine. Conclusions Fluvastatin inhibits the overexpression of TGF -β1 mRNA, which may be related to independent cholesterol decreasing effect.
作者 水华 王群
出处 《中国医师杂志》 CAS 2008年第5期587-589,共3页 Journal of Chinese Physician
关键词 糖尿病 普伐他丁/药理学 肾/药物作用 Diabetes mellitus Pravastatin/PD Kidney/DE
  • 相关文献

参考文献8

  • 1Kanwar YS, Akagi S, Sun L, et al. Cell biology of diabetic kidney disease. Nephron Exp Nephrol, 2005,101 : 100.
  • 2Guo BL, Daisuke K, Motohide I, et al. Peroxisome proliferator activated receptor-gamma ligands inhibit TGF-β-induced fibronectin expression in glomerularmesangial cells. Diabetes, 2004,53 : 200-208.
  • 3Katoh M, Kurosawa Y, Tanaka K, et al. Fluvastatin inhibits 02 and ICAM- 1 levels in a rat model with aortic remodeling induced by pressure overload. Am J Physiol Heart Circ Physiol,2001,281:655-660.
  • 4Wang W, Koka V, Lan HY. Transforming growth factor - beta and Smad signalling in kidney diseases. Nephrology, 2005, 10 : 48 - 56.
  • 5Hill C, Flyvbjerg A, Gronbaek H, et al. The renal expression of transforming growth factor beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology, 2000,141 : 1196-2081.
  • 6Gross JL, de AzevedoMJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment Diabetes Care, 2005, 28: 164-176.
  • 7Usui H , Shikata K, Mat suda M , et al . HMG-CoA reductase inhibitor ameliorates diabetic nephropat hy by it s pleiot ropic effects in rat s . Nephrol Dial Transplant,2003,18 : 265-272.
  • 8Holstein SA, Wohlford-Lenane CL, Hohl RJ, et al. Consequences of mevalonate depletion. Differential transcriptional , translational, and post- translational up-regulation of Ras , Rapl a , RhoA, and RhoB. J Biol Chem, 2002, 277 : 10678-1068.

同被引文献12

  • 1Zairis MN, Adamopoulou EN, Manousakis S J, et al. The impact of hs C-reactive protein and other inflammatory biomarkcrs on long- term cardiovascular mogality in patients with acute coronary syn- dromes. Athemsclerosis,2007,194(2) :397-402.
  • 2Li J, Jin C, Cleveland JC Jr, et al. Enhanced inflammatory re- sponses to toll-like receptor 2/4 stimulation in type 1 diabetic coro- nary artery endothelial cells: the effect of insin. Cardiovasc Dia- beto1,2010 ,9 :90.
  • 3Wei M, Ong L, Smith MT, et al. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ. 2003 ;12( 1 ) :44-50.
  • 4汪新猷.医学实验动物学.北京:人民军医出版社,2000:275-278.
  • 5Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflarmnatory state: a translational perspective. Expert Rev Endocrinol Metab, 2010,5 ( 1 ) : 19-28.
  • 6Kurien BT. Inhibition of p300 and nuclear factor-kappa8 by cur- cumin and its role in diabetic nephropathy. Nutrition, 2009,25(9) :973-974; author reply 975-976.
  • 7Ndisang JF, Jadhav A. Heme oxygenase system enhances insulin sensitivity and glucose metabolism in streptozotocin-induced diabe- tes. Am J Physiol Metab ,2009,296 (4) : E829-E841.
  • 8Pepper C, Hewamana S, Brennan P, et al. NF-kappaB as a prognos- tic marker and therapeutic target in chronia lymphocytic leukemia. Future Oncol,2009,5 ( 7 ) : 1027-1037.
  • 9Papa S, Bubici C,Zazzeroni F, et al. Mechanisms of liver disease : cross-talk between the NF-kappaB and JNK pathwas. Biol Chem, 2009,390 ( 10 ) : 965-976.
  • 10Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and canner. Trends Cell Biol, 2009,19 ( 8 ) : 404- 413.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部